Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.23 USD
−27.99 M USD
0.00 USD
144.30 M
About IMMUTEP LIMITED
Sector
Industry
CEO
Marc Voigt
Website
Headquarters
Sydney
Founded
1987
FIGI
BBG002WD6SY6
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.